New Delhi: The number of farmers on board the Centre’s scheme for the formation and promotion of Farmer Producer Organisations (FPOs) has touched the 30 lakh mark in the country, with around 40 per cent of them being women, according to a statement issued by the Ministry of Agriculture on Friday. These FPOs are now…
Read More “30 Lakh Farmers Come On Board Centres FPO Scheme To Boost Earnings” »
The Amgen logo is displayed outside Amgen headquarters in Thousand Oaks, California, on May 17, 2023. Mario Tama | Getty Images Amgen on Tuesday said its experimental weight loss injection helped patients with obesity lose up to 20% of their weight on average after a year in a critical mid-stage trial, as the company races…
Read More “Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau” »
The director of the IMF Asia Pacific department, Krishna Srinivasan, revealed that India will continue to be the world’s fastest-growing economy, as long as the country’s macroeconomic fundamentals remain strong.In an interview on Tuesday, he told PTI, “India is expected to remain the fastest-growing economy in the world. We project growth at seven percent in…
Eli Lilly’s highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with prediabetes compared with a placebo, according to initial results from a long-term study released Tuesday. The late-stage trial on tirzepatide, the active ingredient in the company’s weight loss injection Zepbound and diabetes…
An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters All doses of Eli Lilly’s highly popular weight loss injection Zepbound and diabetes drug Mounjaro are now available in the U.S., according to an update on the U.S. Food and Drug…
Read More “Eli Lilly’s Zepbound and Mounjaro now available in U.S. after shortages, FDA says” »
The Food and Drug Administration on Tuesday approved a drug from Merck designed to treat a progressive and life-threatening lung condition in a win for both the drugmaker and for patients suffering from the rare disease. The agency greenlighted the therapy, which will be marketed as Winrevair, for adults with pulmonary arterial hypertension. The decision…
Read More “FDA approves Merck’s drug for rare, deadly lung condition” »
A Humana Inc. office building in Louisville, Kentucky, Feb. 3, 2019. Bloomberg | Bloomberg | Getty Images Shares of Humana plummeted Thursday after the health insurer issued dismal full-year earnings guidance, citing soaring medical costs that are dogging the broader insurance industry. Those expenses have spiked as an increasing number of older adults return to…
Read More “Humana stock plunges on dismal 2024 forecast, as insurers face soaring medical costs” »
George Frey | Bloomberg | Getty Images Weight loss drugs exploded into the public eye this year, and 2024 will bring more change to the evolving market. The drugs skyrocketed in popularity in 2023 as they helped patients shed significant weight, despite hefty price tags, mixed insurance coverage and a handful of unpleasant side effects. …
Read More “The weight loss drug boom isn’t over yet — here’s what to expect in the year ahead” »
A doctor vaccinates an infant against respiratory syncytial virus (RSV) in a treatment room of her paediatric practice. Swen Pförtner | Picture Alliance | Getty Images The Centers for Disease Control and Prevention on Friday recommended Pfizer‘s maternal vaccine that protects infants from respiratory syncytial virus, putting the shot on track to be available in the U.S. this fall….
)
